191 related articles for article (PubMed ID: 19159286)
1. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).
Flatt B; Martin R; Wang TL; Mahaney P; Murphy B; Gu XH; Foster P; Li J; Pircher P; Petrowski M; Schulman I; Westin S; Wrobel J; Yan G; Bischoff E; Daige C; Mohan R
J Med Chem; 2009 Feb; 52(4):904-7. PubMed ID: 19159286
[TBL] [Abstract][Full Text] [Related]
2. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Evans MJ; Mahaney PE; Borges-Marcucci L; Lai K; Wang S; Krueger JA; Gardell SJ; Huard C; Martinez R; Vlasuk GP; Harnish DC
Am J Physiol Gastrointest Liver Physiol; 2009 Mar; 296(3):G543-52. PubMed ID: 19136377
[TBL] [Abstract][Full Text] [Related]
3. Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates.
Lundquist JT; Harnish DC; Kim CY; Mehlmann JF; Unwalla RJ; Phipps KM; Crawley ML; Commons T; Green DM; Xu W; Hum WT; Eta JE; Feingold I; Patel V; Evans MJ; Lai K; Borges-Marcucci L; Mahaney PE; Wrobel JE
J Med Chem; 2010 Feb; 53(4):1774-87. PubMed ID: 20095622
[TBL] [Abstract][Full Text] [Related]
4. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR).
Mehlmann JF; Crawley ML; Lundquist JT; Unwalla RJ; Harnish DC; Evans MJ; Kim CY; Wrobel JE; Mahaney PE
Bioorg Med Chem Lett; 2009 Sep; 19(18):5289-92. PubMed ID: 19683924
[TBL] [Abstract][Full Text] [Related]
5. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
Zhang Y; Wang X; Vales C; Lee FY; Lee H; Lusis AJ; Edwards PA
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2316-21. PubMed ID: 16825595
[TBL] [Abstract][Full Text] [Related]
6. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
[TBL] [Abstract][Full Text] [Related]
7. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta--a study on maternal cholestasis model.
Wu WB; Xu YY; Cheng WW; Wang YX; Liu Y; Huang D; Zhang HJ
Placenta; 2015 May; 36(5):545-51. PubMed ID: 25747729
[TBL] [Abstract][Full Text] [Related]
8. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.
Hartman HB; Gardell SJ; Petucci CJ; Wang S; Krueger JA; Evans MJ
J Lipid Res; 2009 Jun; 50(6):1090-100. PubMed ID: 19174369
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia.
Genin MJ; Bueno AB; Agejas Francisco J; Manninen PR; Bocchinfuso WP; Montrose-Rafizadeh C; Cannady EA; Jones TM; Stille JR; Raddad E; Reidy C; Cox A; Michael MD; Michael LF
J Med Chem; 2015 Dec; 58(24):9768-72. PubMed ID: 26568144
[TBL] [Abstract][Full Text] [Related]
10. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
[TBL] [Abstract][Full Text] [Related]
11. Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.
Richter HG; Benson GM; Bleicher KH; Blum D; Chaput E; Clemann N; Feng S; Gardes C; Grether U; Hartman P; Kuhn B; Martin RE; Plancher JM; Rudolph MG; Schuler F; Taylor S
Bioorg Med Chem Lett; 2011 Feb; 21(4):1134-40. PubMed ID: 21269824
[TBL] [Abstract][Full Text] [Related]
12. Targeting farnesoid X receptor for liver and metabolic disorders.
Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
Jiang T; Wang XX; Scherzer P; Wilson P; Tallman J; Takahashi H; Li J; Iwahashi M; Sutherland E; Arend L; Levi M
Diabetes; 2007 Oct; 56(10):2485-93. PubMed ID: 17660268
[TBL] [Abstract][Full Text] [Related]
14. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis.
Cariou B
Diabetes Metab; 2008 Dec; 34(6 Pt 2):685-91. PubMed ID: 19195631
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes.
Richter HG; Benson GM; Blum D; Chaput E; Feng S; Gardes C; Grether U; Hartman P; Kuhn B; Martin RE; Plancher JM; Rudolph MG; Schuler F; Taylor S; Bleicher KH
Bioorg Med Chem Lett; 2011 Jan; 21(1):191-4. PubMed ID: 21134747
[TBL] [Abstract][Full Text] [Related]
16. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists.
Zhang S; Liu Q; Wang J; Harnish DC
Biochem Biophys Res Commun; 2009 Feb; 379(2):476-9. PubMed ID: 19118524
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
[TBL] [Abstract][Full Text] [Related]
18. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
MartÃnez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
20. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand.
Takahashi M; Kanayama T; Yashiro T; Kondo H; Murase T; Hase T; Tokimitsu I; Nishikawa J; Sato R
Biochem Biophys Res Commun; 2008 Aug; 372(3):395-9. PubMed ID: 18457666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
